Rachel Legmann
Senior Director of Technology, Gene Therapy, Repligen Corporation
Rachel Leggman has over 25 years of experience in scalable biologics and in gene therapy manufacturing of therapeutic products. She completed her Ph.D. in Food Engineering and Biotechnology at the Technion-Israel Institute of Technology in Israel. Rachel joined Repligen in 2021 as a subject matter expert, leading the global gene therapy organization to help customers achieve their technical and operational objectives in manufacturing vector-based therapeutics and vaccines, with a focus on gene therapy processes including upstream, downstream, analytics, and scalability. Prior to joining Repligen, Rachel held several scientific and leadership roles: at the Microbiology & Molecular Genetics Department at Harvard Medical School; at SBH Sciences, a CRO; at Seahorse Biosciences, part of Agilent; at Goodwin Biotechnology, a CDMO; and at Pall Corp/Danaher.